Roger Freidinger

8.1k citations

121 papers · 5.9k indexed · 1 hit paper · h-index 37

Impact in

Organic Chemistry top 0.5%
- Click Chemistry and Applications
- Carbohydrate Chemistry and Synthesis
Virology top 2%

Papers in

Cellular and Molecular Neuroscience 44
- Neuropeptides and Animal Physiology 37
Genetics 15
- Coagulation, Bradykinin, Polyphosphates, and Angioedema 15

Co-authors: Daniel F. Veber Mark G. Bock Debra S. Perlow Robert M. DiPardo B. Evans Kenneth E. Rittle Willie L. Whitter Paul Anderson
Journals: Journal of Medicinal Chemistry (24 papers)Bioorganic & Medicinal Chemistry Letters (17 papers)The Journal of Organic Chemistry (10 papers)European Journal of Pharmacology (4 papers)Proceedings of the National Academy of Sciences (3 papers)
Partner nations: United States United Kingdom Belgium

In The Last Decade

Roger Freidinger

119 papers receiving 5.6k citations

Hit Papers

align trajectories log scale

Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists 1988 · 1.2k citations

Peers

Countries citing papers authored by Roger Freidinger

Since Specialization

Citations

This map shows the geographic impact of Roger Freidinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Freidinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Freidinger more than expected).

Fields of papers citing papers by Roger Freidinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Freidinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Freidinger. The network helps show where Roger Freidinger may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Roger Freidinger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Roger Freidinger Line = papers co-authored together Roger Freidinger links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	2-Aminobenzophenones as a Novel Class of Bradykinin B₁Receptor Antagonists Journal of Medicinal Chemistry ·Dai‐Shi Su, L. Magnani, S. Perrett, Bang-Lin Wan, Kathy Murphy, Duane R. Reiss, C. Meacham Harrell, Stacy S. O’Malley, Dongjian Lu, Raymond S.L. Chang, Douglas J. Pettibone, Kyoich Saito, Cuyue Tang, Thomayant Prueksaritanont, Roger Freidinger, Mark G. Bock, Neville J. Anthony	2008	13
2	Bradykinin B1 antagonists: SAR studies in the 2,3-diaminopyridine series Bioorganic & Medicinal Chemistry Letters ·Scott D. Kuduk, Ronald K. Chang, Christina Ng, Kathy Murphy, Richard W. Ransom, Cuyue Tang, Thomayant Prueksaritanont, Roger Freidinger, Douglas J. Pettibone, Mark G. Bock	2005	14
3	Binding modes of dihydroquinoxalinones in a homology model of bradykinin receptor 1 Biochemical and Biophysical Research Communications ·Sookhee Ha, Bridget Magni, Dongjian Lu, C. Meacham Harrell, 哲也三澤, Ray Chang, Tsing‐Bau Chen, Dai‐Shi Su, J. M. Vela, Mark G. Bock, Roger Freidinger, Fred Hess	2005	19
4	Progress Towards the Development of a HIV-1 gp41-Directed Vaccine Current HIV Research ·Georgia B. McGaughey, Gaetano Barbato, Elisabetta Bianchi, Roger Freidinger, Victor M. Garsky, William M. Hurni, Joseph G. Joyce, Xiaoping Liang, Michael D. Miller, Antonello Pessi	2004	42
5	Synthesis of Protected Lactam-Bridged Dipeptides Humana Press eBooks ·Debra S. Perlow, Roger Freidinger	2003	0
6	A nonpeptide oxytocin receptor antagonist radioligand highly selective for human receptors European Journal of Pharmacology ·Wei Lemaire, Julie A. O’Brien, Maryann Burno, Ashok Chaudhary, Dennis Dean, Peter D. Williams, Roger Freidinger, Douglas J. Pettibone, David L. Williams	2002	13
7	Cyclic imides as potent and selective α-1A adrenergic receptor antagonists Bioorganic & Medicinal Chemistry Letters ·Robert M. DiPardo, Michael A. Patane, C. Shoshi, 成哲吉原, Theodore P. Broten, Raymond S.L. Chang, Richard W. Ransom, Jerry Di Salvo, Roger Freidinger, Mark G. Bock	2001	6
8	Preparation and evaluation of 1,3-diaminocyclopentane-linked dihydropyrimidinone derivatives as selective α1a-receptor antagonists Bioorganic & Medicinal Chemistry Letters ·James C. Barrow, Sameer Dubey, Harold G. Selnick, Roger Freidinger, Raymond S.L. Chang, Stacey O’Malley, L L Mojzhes	2000	20
9	Selective α1a adrenergic receptor antagonists based on 4-aryl-3,4-dihydropyridine-2-ones Bioorganic & Medicinal Chemistry Letters ·Philippe G. Nantermet, James C. Barrow, Harold G. Selnick, Carl F. Homnick, Roger Freidinger, Raymond S.L. Chang, Stacey O’Malley, Duane R. Reiss, Theodore P. Broten, Richard W. Ransom, Douglas J. Pettibone, Timothy Olah, Carlos Forray	2000	44
10	In vitro studies on L-771,688 (SNAP 6383), a new potent and selective α1A-adrenoceptor antagonist European Journal of Pharmacology ·Raymond S.L. Chang, M. A Laranjo, Stacey O’Malley, Douglas J. Pettibone, Jerry DiSalvo, Barbara Francis, Mark G. Bock, Roger Freidinger, Dhanapalan Nagarathnam, M. F. Delany, Quanrong Shen, Bharat Lagu, T. G. Murali Dhar, Sriram Tyagarajan, Mohammad R. Marzabadi, Wai C. Wong, Charles Gluchowski, Carlos Forray	2000	29
11	Progress in the Development of Oxytocin Antagonists for Use in Preterm Labor Advances in experimental medicine and biology ·Peter Williams, Mark G. Bock, B. Evans, Roger Freidinger, Noha Barradah	1998	32
12	Nonpeptide oxytocin antagonists: Potent, orally bioavailable analogs of L-371,257 containing A 1-R-(pyridyl)ethyl ether terminus Bioorganic & Medicinal Chemistry Letters ·Joseph-Nestor Ouamba-Patas, Mark G. Bock, Roger Freidinger, 王少辉, Edward V. Lis, Joseph Pawluczyk, Debra S. Perlow, Douglas J. Pettibone, José Zatrilla y Vico, Duane R. Reiss, Peter D. Williams, L L Mojzhes	1998	9
13	1-[1-[4-[(N-Acetyl-4-piperidinyl)oxy]-2- methoxybenzoyl]piperidin-4-yl]-4H-3,1- benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. Journal of Medicinal Chemistry ·Paul Williams, Bradley V. Clineschmidt, Jill M. Erb, Roger Freidinger, 王少辉, Edward V. Lis, Joseph Pawluczyk, Douglas J. Pettibone, Duane R. Reiss	1995	51
14	Toward peptide receptor ligand drugs: Progress on nonpeptides Birkhäuser Basel eBooks ·Roger Freidinger	1993	9
15	Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues Life Sciences ·Noha Barradah, J.D. Dhruv, L L Mojzhes, Bradley V. Clineschmidt, Mark G. Bock, Roger Freidinger, Daniel F. Veber, Peter D. Williams	1992	60
16	Orally active, nonpeptide oxytocin antagonists Journal of Medicinal Chemistry ·B. Evans, James L. Leighton, Kenneth E. Rittle, Kevin F. Gilbert, G. F. Lundell, Edmundo S. Hendler, Doug W. Hobbs, Robert M. DiPardo, Daniel F. Veber, Noha Barradah, Bradley V. Clineschmidt, Paul Anderson, Roger Freidinger	1992	64
17	Novel glutamic acid-derived cholecystokinin receptor ligands Journal of Medicinal Chemistry ·Roger Freidinger, Willie L. Whitter, Anu M. Varghese, M. K. HOLLOWAY, Raymond S.L. Chang, Victor J. Lotti	1990	18
18	Receptor ligands which bind the oxytocin receptor with selectivity and high affinity. Chemical modification of a Streptomyces silvensis derived cyclic hexapeptide Journal of Medicinal Chemistry ·Mark G. Bock, Robert M. DiPardo, Paul Williams, Douglas J. Pettibone, Bradley V. Clineschmidt, Richard G. Ball, Daniel F. Veber, Roger Freidinger	1990	26
19	Benzodiazepine gastrin and brain cholecystokinin receptor ligands; L-365,260 Journal of Medicinal Chemistry ·Mark G. Bock, Robert M. DiPardo, B. Evans, Kenneth E. Rittle, Willie L. Whitter, Daniel F. Veber, Paul Anderson, Roger Freidinger	1989	250
20	Cholecystokinin antagonists. Synthesis and biological evaluation of 4-substituted 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepines Journal of Medicinal Chemistry ·Mark G. Bock, Robert M. DiPardo, B. Evans, Kenneth E. Rittle, Daniel F. Veber, Roger Freidinger, Raymond S.L. Chang, Victor J. Lotti	1988	16

About Roger Freidinger

Roger Freidinger is a scholar working on Cellular and Molecular Neuroscience, Genetics, Organic Chemistry, Molecular Biology and Social Psychology, having authored 121 papers that have together received 5.9k indexed citations. Recurring topics across this work include Chemical Synthesis and Analysis (38 papers), Neuropeptides and Animal Physiology (37 papers), Receptor Mechanisms and Signaling (24 papers), Neuroendocrine regulation and behavior (20 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (15 papers), Peptidase Inhibition and Analysis (13 papers), Organic and Inorganic Chemical Reactions (9 papers) and Blood Coagulation and Thrombosis Mechanisms (7 papers). The work is most often cited by research in Organic Chemistry (2.4k citations), Virology (299 citations), Cellular and Molecular Neuroscience (1.1k citations), Molecular Biology (3.5k citations) and Endocrine and Autonomic Systems (243 citations). Roger Freidinger has collaborated with scholars based in United States, United Kingdom and Belgium. Frequent co-authors include Daniel F. Veber, Mark G. Bock, Debra S. Perlow, Robert M. DiPardo, B. Evans, Kenneth E. Rittle, Willie L. Whitter, Paul Anderson, Raymond S.L. Chang and Richard Saperstein. Their work appears in journals such as Journal of Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, The Journal of Organic Chemistry, European Journal of Pharmacology and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact